Evidence map›Paper›PMID 26024945›Full record

ArticleJournal of biomolecular screening2015

A Cell-Based Internalization and Degradation Assay with an Activatable Fluorescence-Quencher Probe as a Tool for Functional Antibody Screening.

Yan Li, Peter Corbett Liu, Yang Shen, Marshall D Snavely, Kaori Hiraga

Open access · hybridAbstract read
In one paragraph

Article in Journal of biomolecular screening, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. mAbs
    Article
  11. Dose-Dependent Internalization and Externalization Integrity Study of Newly SynthesizedDose-response : a publication of International Hormesis Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yan LiAntibody Technology, Eli Lilly and Company, New York, NY, USA yan.li@lilly.com.
Peter Corbett LiuAntibody Technology, Eli Lilly and Company, New York, NY, USA.
Yang ShenAntibody Technology, Eli Lilly and Company, New York, NY, USA.
Marshall D SnavelyAntibody Technology, Eli Lilly and Company, New York, NY, USA.
Kaori HiragaAntibody Technology, Eli Lilly and Company, New York, NY, USA.
Eli Lilly (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For the development of therapeutically potent anti-cancer antibody drugs, it is often important to identify antibodies that internalize into cells efficiently, rather than just binding to antigens on the cell surface. Such antibodies can mediate receptor endocytosis, resulting in receptor downregulation on the cell surface and potentially inhibiting receptor function and tumor growth. Also, efficient antibody internalization is a prerequisite for the delivery of cytotoxic drugs into target cells and is critical for the development of antibody-drug conjugates. Here we describe a novel activatable fluorescence-quencher pair to quantify the extent of antibody internalization and degradation in the target cells. In this assay, candidate antibodies were labeled with a fluorescent dye and a quencher. Fluorescence is inhibited outside and on the surface of cells, but activated upon endocytosis and degradation of the antibody. This assay enabled the development of a process for rapid characterization of candidate antibodies potentially in a high-throughput format. By employing an activatable secondary antibody, primary antibodies in purified form or in culture supernatants can be screened for internalization and degradation. Because purification of candidate antibodies is not required, this method represents a direct functional screen to identify antibodies that internalize efficiently early in the discovery process.

Indexed as

Fluorescent Antibody TechniqueFluorescent DyesAntibodies, MonoclonalAntineoplastic AgentsCell Line, TumorDrug Screening Assays, AntitumorFlow CytometryHigh-Throughput Screening AssaysHumansImmunoconjugatesProtein TransportProteolysisAntibodies, MonoclonalAntineoplastic AgentsFluorescent DyesImmunoconjugatesantibody labelingantibody screeningcell-based assaydegradationflow cytometryfluorescent dyeinternalizationquencher dye

Identifiers

PMID26024945
PMCPMC4512523
OpenAlexW1872036180

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.